Literature DB >> 16406521

Osteopontin: role in cell signaling and cancer progression.

Hema Rangaswami1, Anuradha Bulbule, Gopal C Kundu.   

Abstract

Cell migration and degradation of the extracellular matrix (ECM) are crucial steps in tumor progression. Several matrix-degrading proteases, including matrix metalloproteases, are highly regulated by growth factors, cytokines and ECM proteins. Osteopontin (OPN), a chemokine-like, calcified ECM-associated protein, plays a crucial role in determining the metastatic potential of various cancers. Since its first identification in bone, the multifaceted roles of OPN have been an area of intense investigation. Extensive research has elucidated the pivotal role of OPN in regulating the cell signaling that controls tumor progression and metastasis. This review focuses on recent advances in understanding the functional role of the OPN-induced signaling pathway in the regulation of cell migration and tumor progression and the implications for identifying novel targets for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406521     DOI: 10.1016/j.tcb.2005.12.005

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  246 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions.

Authors:  Christina Reufsteck; Rinat Lifshitz-Shovali; Michael Zepp; Tobias Bäuerle; Dieter Kübler; Gershon Golomb; Martin R Berger
Journal:  Clin Exp Metastasis       Date:  2012-03-11       Impact factor: 5.150

Review 3.  Biomarkers predicting malignant progression of laryngeal epithelial precursor lesions: a systematic review.

Authors:  Juan P Rodrigo; Juana María García-Pedrero; Carlos Suárez; Robert P Takes; Lester D R Thompson; Pieter J Slootweg; Julia A Woolgar; William H Westra; Ruud H Brakenhoff; Alessandra Rinaldo; Kenneth O Devaney; Michelle D Williams; Douglas R Gnepp; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-12       Impact factor: 2.503

4.  Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells.

Authors:  Carolina Castilla; M Luz Flores; José M Conde; Rafael Medina; Francisco J Torrubia; Miguel A Japón; Carmen Sáez
Journal:  Clin Exp Metastasis       Date:  2012-01-25       Impact factor: 5.150

5.  The dual role of osteopontin in acetaminophen hepatotoxicity.

Authors:  Chun-yan He; Bei-bei Liang; Xiao-yu Fan; Lei Cao; Rui Chen; Ya-jun Guo; Jian Zhao
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

Review 6.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 7.  Emerging Roles of Electrospun Nanofibers in Cancer Research.

Authors:  Shixuan Chen; Sunil Kumar Boda; Surinder K Batra; Xiaoran Li; Jingwei Xie
Journal:  Adv Healthc Mater       Date:  2017-12-06       Impact factor: 9.933

8.  Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma?

Authors:  Yoo Jin Lee; Byoung Kuk Jang
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

9.  Expression and purification of non-tagged recombinant mouse SPP1 in E. coli and its biological significance.

Authors:  Shunyan Weng; Liang Zhou; Lei Han; Yunsheng Yuan
Journal:  Bioengineered       Date:  2014-10-30       Impact factor: 3.269

10.  Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.

Authors:  Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Hellmuth-A Meyer; Stefan A Loening; Klaus Jung
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.